In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
March 23rd, 2022
2.3K views
We describe a preclinical experimental method to evaluate metabolic neuromodulation induced by acute deep brain stimulation with in vivo FDG-PET. This manuscript includes all experimental steps, from stereotaxic surgery to the application of the stimulation treatment and the acquisition, processing, and analysis of PET images.
Overview
This study presents a preclinical method to evaluate metabolic neuromodulation resulting from acute deep brain stimulation (DBS) using in vivo FDG-PET imaging. The protocol outlines all experimental steps, including surgical procedures and image acquisition, aimed at understanding the effects of DBS on brain dynamics.
Key Study Components
Area of Science
- Neuroscience
- Neuroimaging
- Neuromodulation
Background
- Deep brain stimulation (DBS) is utilized in neurological and psychiatric conditions.
- The effects of DBS on neural networks are not fully understood.
- In vivo imaging techniques allow visualization of metabolic changes during stimulation.
- FDG-PET imaging is particularly useful for assessing brain metabolic activity.
Purpose of Study
- To evaluate the consequences of DBS on brain dynamics.
- To refine stimulation protocols based on observed metabolic changes.
- To enhance understanding of DBS mechanisms within neural networks.
Methods Used
- The study employs in vivo FDG-PET imaging to assess metabolic changes.
- Rat models were used for stereotaxic surgery and electrode implantation.
- CT and MRI scans were conducted to ensure electrode placement accuracy.
- Key procedural steps involved preparing the animal, performing surgery, and injecting radiotracers for imaging.
Main Results
- Significant metabolic differences in FDG uptake were observed following DBS.
- Imaging revealed variations in brain dynamics as a consequence of stimulation.
- T-maps provided insights into increased and decreased metabolic activity across brain regions.
- The findings contribute to refining DBS techniques and understanding their neural impacts.
Conclusions
- This study demonstrates an effective method for visualizing and evaluating the effects of DBS on brain metabolism.
- The insights gained could help improve DBS strategies and enhance our understanding of underlying neuronal mechanisms.
- The approach has implications for both clinical applications and basic neuroscience research.
Frequently Asked Questions
What are the advantages of using in vivo FDG-PET imaging?
In vivo FDG-PET imaging allows for real-time visualization of metabolic changes in the brain during deep brain stimulation, offering insights into neural circuit dynamics.
How is the animal model prepared for surgery?
The anesthetized rat is positioned supine on a stereotactic frame, and the surgical area is carefully prepared, including securing the head and applying antiseptic solutions.
What types of data are obtained from this method?
This method yields imaging data reflecting metabolic activity changes, allowing for the analysis of altered brain dynamics due to stimulation.
How can the method be adapted for different studies?
The protocol can be modified to include different stimulation parameters or imaging modalities based on specific research questions or animal models.
What are some limitations of this approach?
Limitations include the need for precise electrode placement and potential variability in metabolic responses among different animals.
Executive Industry Relevance
Integrating in vivo FDG-PET imaging with deep brain stimulation (DBS) in preclinical models enables direct visualization of neuromodulatory effects on brain metabolism, supporting mechanistic de-risking in CNS target validation. This approach enhances predictive confidence for translational neuroscience portfolios by quantifying acute metabolic responses to DBS protocols. The method informs early-stage decision-making for neuromodulation strategies in neuropsychiatric and neurological disorder pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of neuromodulatory hypotheses by mapping DBS-induced metabolic changes in vivo.
- Supports functional target validation through quantitative assessment of brain region activity patterns.
- Facilitates mechanistic de-risking by revealing acute neural network responses to stimulation.
- Provides data to triage neuromodulation targets based on observed metabolic modulation.
Screening & Assay Development
- Establishes validated preclinical models for evaluating neuromodulation protocols.
- Delivers reproducible, quantitative imaging outputs for assay standardization.
- Enables screening of stimulation parameters for optimal metabolic impact.
- Supports platform reuse for comparative studies across neuromodulation candidates.
Translational & Preclinical Research
- Aligns preclinical metabolic readouts with translational biomarker strategies in CNS research.
- Provides continuity from discovery-stage neuromodulation to preclinical validation of brain activity modulation.
- Informs risk-adjusted advancement of DBS protocols based on in vivo metabolic evidence.
- Supports predictive de-risking for CNS therapeutic development pipelines.
Pipeline & Workflow Integration
This protocol positions FDG-PET imaging of DBS effects at the intersection of early discovery, target validation, and preclinical model optimization in CNS drug development.
- Discovery Biology: Quantifies acute metabolic shifts to test neuromodulation hypotheses and clarify neural pathways.
- Screening: Provides reproducible imaging metrics for evaluating stimulation protocols and parameter sets.
- Analytics: Generates voxel-wise statistical outputs (T-maps, P-values) for robust condition comparison.
- Translational Research: Bridges preclinical metabolic findings to potential clinical biomarker strategies.
- Enterprise Reuse: Offers a standardized imaging workflow adaptable across neuromodulation research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in CNS target validation.
- Operational Value: Delivers standardized, reproducible imaging data for cross-study comparability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient prioritization of neuromodulation assets.
- Portfolio Impact: Supports risk-adjusted advancement and de-risking of CNS therapeutic candidates.
Implementation Considerations
- Requires expertise in stereotactic surgery, neuroimaging, and quantitative image analysis.
- Demands access to PET/CT imaging infrastructure and radiotracer handling capabilities.
- Necessitates rigorous cross-team standardization of surgical and imaging protocols.
- Adaptation across animal models may require protocol optimization for electrode placement and imaging parameters.
- Precision in electrode targeting and metabolic measurement is critical for reliable data interpretation.
Biopharma FAQs
Why does null hypothesis testing of paired FDG-PET scans matter for target validation?
Paired FDG-PET scans analyzed with voxel-wise statistical tests enable objective assessment of DBS-induced metabolic changes, providing quantitative evidence for or against neuromodulation target engagement in preclinical models.
How does independent variable isolation during DBS stimulation fit the discovery pipeline?
Isolating DBS as the independent variable during FDG uptake allows direct attribution of observed metabolic changes to stimulation, strengthening mechanistic insights and supporting early-stage hypothesis testing in CNS discovery workflows.
What do quantitative dependent variable measurements from FDG-PET enable in neuromodulation studies?
Quantitative FDG-PET measurements provide spatially resolved metabolic activity data, enabling comparison of brain region responses and supporting data-driven optimization of stimulation protocols for translational research.
Why are replication requirements critical for cross-functional collaboration in DBS imaging studies?
Replication of imaging and stimulation protocols ensures data reliability and comparability, facilitating collaboration between discovery, imaging, and translational teams and supporting robust portfolio decision-making.
What statistical analysis capabilities are required before implementing voxel-wise PET comparisons?
Robust statistical analysis, including paired T-tests and cluster-level significance assessment, is essential to validate metabolic differences and ensure that observed effects are reproducible and actionable for R&D advancement.
Chapters in this video
0:04
Introduction
0:50
Brain Target Localization by In Vivo Neuroimaging
2:12
Stereotaxic Surgery
5:56
PET-CT Imaging Acquisition
6:46
DBS Stimulator Configuration
7:30
Results: Evaluating the Consequences of Deep Brain Stimulation via In Vivo Neuroimaging
8:46
Conclusion
